Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review
Abstract
:1. Introduction
2. Cases Presentation
2.1. Methods
- -
- Fully recovered children: This group included those that reported no persisting symptoms after acute SARS-CoV-2 infection at the time of follow-up post-onset of acute COVID-19 symptoms (at least 8 weeks).
- -
- Long COVID group: any child with persisting symptoms for at least 12 weeks after SARS-CoV-2 infection, that cannot be explained by an alternative diagnosis and have a negative impact on daily life.
2.2. Case One
2.3. Case Two
3. Discussion
4. Conclusions
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Crook, H.; Raza, S.; Nowell, J.; Young, M.; Edison, P. Long COVID-mechanisms, risk factors, and management. BMJ 2021, 374, n1648. [Google Scholar] [CrossRef]
- Fainardi, V.; Meoli, A.; Chiopris, G.; Motta, M.; Skenderaj, K.; Grandinetti, R.; Bergomi, A.; Antodaro, F.; Zona, S.; Esposito, S. Long COVID in Children and Adolescents. Life 2022, 12, 285. [Google Scholar] [CrossRef]
- Buonsenso, D.; Di Gennaro, L.; De Rose, C.; Morello, R.; D’Ilario, F.; Zampino, G.; Piazza, M.; Boner, A.L.; Iraci, C.; O’Connell, S.; et al. Long-term outcomes of pediatric infections: From traditional infectious diseases to long COVID. Future Microbiol. 2022, 17, 551–571. [Google Scholar] [CrossRef]
- Lopez-Leon, S.; Wegman-Ostrosky, T.; Ayuzo Del Valle, N.C.; Perelman, C.; Sepulveda, R.; Rebolledo, P.A.; Cuapio, A.; Villapol, S. Long-COVID in children and adolescents: A systematic review and meta-analyses. Sci. Rep. 2022, 12, 9950. [Google Scholar] [CrossRef]
- WHO. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (accessed on 6 October 2021).
- Stephenson, T.; Allin, B.; Nugawela, M.D.; Rojas, N.; Dalrymple, E.; Pinto Pereira, S.; Soni, M.; Knight, M.; Cheung, E.Y.; Heyman, I.; et al. Long COVID (post-COVID-19 condition) in children: A modified Delphi process. Arch. Dis. Child. 2022, 107, 674–680. [Google Scholar] [CrossRef]
- Kikkenborg Berg, S.; Dam Nielsen, S.; Nygaard, U.; Bundgaard, H.; Palm, P.; Rotvig, C.; Vinggaard Christensen, A. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): A national, cross-sectional study. Lancet Child. Adolesc. Health 2022, 6, 240–248. [Google Scholar] [CrossRef]
- Piazza, M.; Di Cicco, M.; Pecoraro, L.; Ghezzi, M.; Peroni, D.; Comberiati, P. Long COVID-19 in Children: From the Pathogenesis to the Biologically Plausible Roots of the Syndrome. Biomolecules 2022, 12, 556. [Google Scholar] [CrossRef]
- Buonsenso, D.; Piazza, M.; Boner, A.L.; Bellanti, J.A. Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma. Proc. 2022, 43, 187–193. [Google Scholar] [CrossRef]
- Yong, S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021, 53, 737–754. [Google Scholar] [CrossRef]
- Couzin-Frankel, J. Clues to long COVID. Science 2022, 376, 1261–1265. [Google Scholar] [CrossRef]
- COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19; National Institute for Health and Care Excellence (NICE): London, UK, 2020.
- Rosa, L.; Tripepi, G.; Naldi, E.; Aimati, M.; Santangeli, S.; Venditto, F.; Caldarelli, M.; Valenti, P. Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study. J. Clin. Med. 2021, 10, 4276. [Google Scholar] [CrossRef]
- Scottoni, F.; Giobbe, G.G.; Zambaiti, E.; Khalaf, S.; Sebire, N.J.; Curry, J.; De Coppi, P.; Gennari, F. Intussusception and COVID-19 in Infants: Evidence for an Etiopathologic Correlation. Pediatrics 2022, 149, e2021054644. [Google Scholar] [CrossRef]
- Presti, S.; Manti, S.; Parisi, G.F.; Papale, M.; Barbagallo, I.A.; Li Volti, G.; Leonardi, S. Lactoferrin: Cytokine Modulation and Application in Clinical Practice. J. Clin. Med. 2021, 10, 5482. [Google Scholar] [CrossRef]
- Mattar, E.H.; Elrashdy, F.; Almehdar, H.A.; Uversky, V.N.; Redwan, E.M. Natural resources to control COVID-19: Could lactoferrin amend SARS-CoV-2 infectivity? PeerJ 2021, 9, e11303. [Google Scholar] [CrossRef]
- Parisi, G.F.; Carota, G.; Castruccio Castracani, C.; Spampinato, M.; Manti, S.; Papale, M.; Di Rosa, M.; Barbagallo, I.; Leonardi, S. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature. Int. J. Mol. Sci. 2021, 22, 2465. [Google Scholar] [CrossRef]
- Miotto, M.; Di Rienzo, L.; Bò, L.; Boffi, A.; Ruocco, G.; Milanetti, E. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin. Front. Mol. Biosci. 2021, 8, 607443. [Google Scholar] [CrossRef]
- Gaziano, R.; Pistoia, E.S.; Campione, E.; Fontana, C.; Marino, D.; Favaro, M.; Pica, F.; Di Francesco, P. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 4174–4184. [Google Scholar] [CrossRef]
- Costagliola, G.; Spada, E.; Comberiati, P.; Peroni, D.G. Could nutritional supplements act as therapeutic adjuvants in COVID-19? Ital. J. Pediatr. 2021, 47, 32. [Google Scholar] [CrossRef]
- Mrityunjaya, M.; Pavithra, V.; Neelam, R.; Janhavi, P.; Halami, P.M.; Ravindra, P.V. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front. Immunol. 2020, 11, 570122. [Google Scholar] [CrossRef]
- Kruzel, M.L.; Zimecki, M.; Actor, J.K. Lactoferrin in a Context of Inflammation-Induced Pathology. Front. Immunol. 2017, 8, 1438. [Google Scholar] [CrossRef]
- Rosa, L.; Cutone, A.; Lepanto, M.S.; Paesano, R.; Valenti, P. Lactoferrin: A natural glycoprotein involved in Iron and inflammatory homeostasis. Int. J. Mol. Sci. 2017, 18, 1985. [Google Scholar] [CrossRef] [PubMed]
- Siqueiros-Cendón, T.; Arévalo-Gallegos, S.; Iglesias-Figueroa, B.F.; García-Montoya, I.A.; Salazar-Martínez, J.; Rascón-Cruz, Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol. Sin. 2014, 35, 557–566. [Google Scholar] [CrossRef] [PubMed]
- Zwirzitz, A.; Reiter, M.; Skrabana, R.; Ohradanova-Repic, A.; Majdic, O.; Gutekova, M.; Cehlar, O.; Petrovčíková, E.; Kutejova, E.; Stanek, G.; et al. Lactoferrin is a natural inhibitor of plasminogen activation. J. Biol. Chem. 2018, 293, 8600–8613. [Google Scholar] [CrossRef]
- Campione, E.; Lanna, C.; Cosio, T.; Rosa, L.; Conte, M.P.; Iacovelli, F.; Romeo, A.; Falconi, M.; Del Vecchio, C.; Franchin, E.; et al. Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. Front. Pharmacol. 2021, 12, 666600. [Google Scholar] [CrossRef]
- Salaris, C.; Scarpa, M.; Elli, M.; Bertolini, A.; Guglielmetti, S.; Pregliasco, F.; Blandizzi, C.; Brun, P.; Castagliuolo, I. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro. Nutrients 2021, 13, 328. [Google Scholar] [CrossRef]
- Hu, Y.; Meng, X.; Zhang, F.; Xiang, Y.; Wang, J. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg. Microbes Infect. 2021, 10, 317–330. [Google Scholar] [CrossRef]
- Kell, D.B.; Heyden, E.L.; Pretorius, E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front. Immunol. 2020, 11, 1221. [Google Scholar] [CrossRef]
- Chang, R.; Ng, T.B.; Sun, W.Z. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int. J. Antimicrob. Agents 2020, 56, 106118. [Google Scholar] [CrossRef]
- Campione, E.; Lanna, C.; Cosio, T.; Rosa, L.; Conte, M.P.; Iacovelli, F.; Romeo, A.; Falconi, M.; Del Vecchio, C.; Franchin, E.; et al. Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. Int. J. Environ. Res. Public Health 2021, 18, 10985. [Google Scholar] [CrossRef]
- Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 2021, 93, 250–256. [Google Scholar] [CrossRef]
- Merad, J.; Martin, J.C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 2020, 10, 102–108. [Google Scholar] [CrossRef]
- Martin-Cardona, A.; Lloreta Trull, J.; Albero-González, R.; Paraira Beser, M.; Andújar, X.; Ruiz-Ramirez, P.; Tur-Martínez, J.; Ferrer, C.; De Marcos Izquierdo, J.A.; Pérez-Madrigal, A.; et al. SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: Two case reports. BMC Gastroenterol. 2021, 21, 334. [Google Scholar] [CrossRef]
- Queiroz, V.A.; Assis, A.M.; da Costa, R.; Júnior, H. Protective effect of human lactoferrin in the gastrointestinal tract. Rev. Paul. Pediatr. 2013, 31, 90–95. [Google Scholar] [CrossRef]
- Liao, Y.; Jiang, R.; Lönnerdal, B. Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochem. Cell Biol. 2012, 90, 476–484. [Google Scholar] [CrossRef] [PubMed]
- Vega-Bautista, A.; de la Garza, M.; Carrero, J.C.; Campos-Rodríguez, R.; Godínez-Victoria, M.; Drago-Serrano, M.E. The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria. Int. J. Mol. Sci. 2019, 20, 4707. [Google Scholar] [CrossRef] [PubMed]
- Laffan, A.M.; McKenzie, R.; Forti, J.; Conklin, D.; Marcinko, R.; Shrestha, R.; Bellantoni, M.; Greenough, W.B., III. Lactoferrin for the prevention of post-antibiotic diarrhoea. J. Health Popul. Nutr. 2011, 29, 547–551. [Google Scholar] [CrossRef]
- Campos-Martinez, A.M.; Expósito-Herrera, J.; Gonzalez-Bolívar, M.; Fernández-Marin, E.; Uberos, J. Evaluation of Risk and Preventive Factors for Necrotizing Enterocolitis in Premature Newborns. A Systematic Review of the Literature. Front. Pediatr. 2022, 10, 874976. [Google Scholar] [CrossRef] [PubMed]
- D’Amico, F.; Decembrino, N.; Muratore, E.; Turroni, S.; Muggeo, P.; Mura, R.; Perruccio, K.; Vitale, V.; Zecca, M.; Prete, A.; et al. Oral Lactoferrin Supplementation during Induction Chemotherapy Promotes Gut Microbiome Eubiosis in Pediatric Patients with Hematologic Malignancies. Pharmaceutics 2022, 14, 1705. [Google Scholar] [CrossRef]
- Zollner, A.; Koch, R.; Jukic, A.; Pfister, A.; Meyer, M.; Rössler, A.; Kimpel, J.; Adolph, T.E.; Tilg, H. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology 2022, 163, 495–506.e8. [Google Scholar] [CrossRef]
- Peluso, M.J.; Deeks, S.G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022, 43, 268–270. [Google Scholar] [CrossRef]
- Cocciolillo, F.; Di Giuda, D.; Morello, R.; De Rose, C.; Valentini, P.; Buonsenso, D. Orbito-Frontal Cortex Hypometabolism in Children with Post-COVID Condition (Long COVID): A Preliminary Experience. Pediatr. Infect. Dis. J. 2022, 41, 663–665. [Google Scholar] [CrossRef] [PubMed]
- Buonsenso, D.; Di Giuda, D.; Sigfrid, L.; Pizzuto, D.A.; Di Sante, G.; De Rose, C.; Lazzareschi, I.; Sali, M.; Baldi, F.; Chieffo, D.P.R.; et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child. Adolesc. Health 2021, 5, 677–680. [Google Scholar] [CrossRef]
- Buonsenso, D.; Martino, L.; Morello, R.; De Rose, C.; Valentini, P. Chronic Olfactory Dysfunction in Children with Long COVID: A Retrospective Study. Children 2022, 9, 1251. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Morello, R.; De Rose, C.; Cardinali, S.; Valentini, P.; Buonsenso, D. Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children 2022, 9, 1446. https://doi.org/10.3390/children9101446
Morello R, De Rose C, Cardinali S, Valentini P, Buonsenso D. Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children. 2022; 9(10):1446. https://doi.org/10.3390/children9101446
Chicago/Turabian StyleMorello, Rosa, Cristina De Rose, Sara Cardinali, Piero Valentini, and Danilo Buonsenso. 2022. "Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review" Children 9, no. 10: 1446. https://doi.org/10.3390/children9101446
APA StyleMorello, R., De Rose, C., Cardinali, S., Valentini, P., & Buonsenso, D. (2022). Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children, 9(10), 1446. https://doi.org/10.3390/children9101446